MedPath

GE HealthCare's Novel Manganese-Based MRI Contrast Agent Shows Promise in Phase I Trial

• GE HealthCare's first-in-human study of a macrocyclic manganese-based MRI contrast agent demonstrates it was well tolerated with no serious adverse events. • The novel agent offers a potential alternative to gadolinium-based contrast agents, addressing concerns about gadolinium retention and environmental impact. • This manganese-based agent exhibits comparable relaxivity to gadolinium agents, suggesting similar diagnostic capabilities for enhanced visualization in MRI. • The successful Phase I trial supports further clinical development, aligning with GE HealthCare's commitment to innovative contrast media solutions.

GE HealthCare has announced positive Phase I clinical trial results for its novel macrocyclic manganese-based magnetic resonance imaging (MRI) contrast agent. The first-in-human study, presented at the Contrast Media Research symposium in Oslo, Norway, indicated that the agent was well tolerated, with no serious adverse events, dose-limiting toxicities, or clinically relevant findings reported.
This development addresses growing concerns regarding gadolinium-based contrast agents, which are commonly used to enhance MRI images by improving the visualization of abnormal structures and lesions. Gadolinium retention in the body and its potential environmental impact have prompted the search for alternative contrast agents.

Potential Benefits of Manganese-Based Agent

The manganese-based contrast agent offers several potential advantages. Unlike gadolinium, manganese is naturally occurring in the body and is efficiently eliminated. The agent's relaxivity, which is comparable to that of gadolinium-based agents, suggests it could provide similar diagnostic image enhancement. According to Dr. Robert J. McDonald, Radiologist at Mayo Clinic and Contrast Media Safety Committee Board member for the American College of Radiology, GE HealthCare's manganese-based contrast agent could offer benefits such as reduced risk of tissue deposition and improved safety for certain vulnerable patient populations compared to gadolinium-based agents, while also providing comparable imaging capabilities and potentially lower environmental impact.

Clinical Trial Details

The Phase I trial was conducted at Oslo University Hospital, Rikshospitalet, Norway, with partial funding from the Norwegian Research Council. The study evaluated the safety and tolerability of the manganese-based agent in healthy volunteers.

Future Directions

"These are encouraging Phase I results for this manganese-based contrast agent and we look forward to completing the next steps in the clinical development process," said Dr. Paul Evans, Head of Global R&D at GE HealthCare's Pharmaceutical Diagnostics business segment. The company aims to offer radiologists a broader portfolio of contrast agents to enable personalized care and address unmet patient needs.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Bayer's Gadoquatrane Achieves Positive Phase III Results with Reduced Gadolinium Dose

Bayer's investigational MRI contrast agent, gadoquatrane, met primary and secondary endpoints in Phase III QUANTI studies.
Gadoquatrane uses 60% less gadolinium (0.04 mmol Gd/kg) compared to standard macrocyclic GBCAs (0.1 mmol Gd/kg).

Regenxbio Expands MPS I Gene Therapy Trial After Initial Data Review

Regenxbio has decided to expand its phase 1/2 trial for RGX-111, a gene therapy targeting mucopolysaccharidosis type I (MPS I), following promising initial data showing clinical activity. The therapy aims to deliver a functional copy of the IDUA gene to the central nervous system, offering a potential one-shot treatment for this rare inherited disease.

GC Biopharma and Novel Pharma Initiate Phase I Trial of GC1130A for Sanfilippo Syndrome Type A

GC Biopharma and Novel Pharma have dosed the first patient in a multinational Phase I clinical trial of GC1130A for Sanfilippo syndrome type A (MPS IIIA).
The Phase I trial will assess the safety, tolerability, and efficacy of GC1130A in children aged 2-6 years with MPS IIIA over a two-year period.

FluoGuide's FG001 Demonstrates Positive Phase 2 Data in Head and Neck Cancer Surgery

FluoGuide's FG001, a novel imaging agent, has shown promising Phase 2 results in enhancing surgical accuracy for head and neck cancer patients.
The study, published in _Theranostics_, demonstrated 100% sensitivity in illuminating cancerous tissues with excellent tolerability across varying doses.

GE HealthCare's SIGNA MAGNUS Head-Only MRI System Receives FDA Clearance

GE HealthCare's SIGNA MAGNUS, a 3.0T head-only MRI, has received FDA clearance, offering advanced neuroimaging capabilities for clinical and research use.
The SIGNA MAGNUS features an innovative asymmetric gradient coil design, enhancing gradient performance and enabling high-resolution imaging with shorter scan times.

Minghui Pharmaceutical's MHB039A Shows Promise in Phase I Trial for Solid Tumors

Minghui Pharmaceutical's MHB039A demonstrated significant PD-1 receptor occupancy and VEGF biomarker responses in a Phase I trial for relapsed or refractory solid tumors.
The Phase I trial of MHB039A established a recommended Phase II dose (RP2D) of 20 mg/kg administered once every three weeks.

Minghui Pharma's MHB039A Shows Promise in Phase I Trial for Solid Tumors

Minghui Pharmaceutical's MHB039A, a novel PD-1 x VEGF bispecific antibody, demonstrates a favorable safety profile in a Phase I trial for relapsed/refractory solid tumors.
The study observed robust PD-1 receptor occupancy and circulating VEGF biomarker responses across all dose levels, with the 20 mg/kg Q3W regimen showing substantial inhibition.

Minghui Pharmaceutical's MHB039A Shows Promise in Phase I Trial for Solid Tumors

Minghui Pharmaceutical's MHB039A, a PD-1 x VEGF bispecific antibody, demonstrates a favorable safety profile in relapsed/refractory solid tumor patients.
The Phase I trial shows robust PD-1 receptor occupancy and VEGF biomarker responses across all dose levels, with tumor volume reduction in certain NSCLC subtypes.

Maze Therapeutics' MZE829 Shows Promise in Phase I Trial for APOL1 Kidney Disease

Maze Therapeutics' MZE829 demonstrated favorable safety and tolerability in a Phase I trial involving healthy volunteers.
Pharmacokinetic analysis suggests MZE829 is suitable for once-daily oral administration, simplifying dosing for patients.

Georgiamune Doses First Participant in Phase 1 Trial of GIM-407 for Autoimmune Diseases

Georgiamune has dosed the first participant in a Phase 1 trial of GIM-407, an oral, selective T-regulatory cell activator, for autoimmune diseases.
GIM-407 represents Georgiamune's first autoimmune disease program and is based on novel biology, with potential application to various autoimmune conditions.

Reference News

[1]
GE HealthCare Announces Phase I Results for a First-of-its-Kind Macrocyclic Manganese ...
via.ritzau.dk · Oct 7, 2024

GE HealthCare's Phase I clinical trial of a novel manganese-based MRI contrast agent showed it was well tolerated with n...

[2]
GE HealthCare Announces Phase I Results for a First-of-its-Kind Macrocyclic Manganese ...
quantisnow.com · Oct 7, 2024

GE HealthCare's novel manganese-based MRI contrast agent, tested in a Phase I trial, showed no serious adverse events an...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy